{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:43:32Z","timestamp":1763037812269,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. We defined the biology of GZ17-6.02 in prostate cancer cells and determined whether it interacted with the PARP1 inhibitor olaparib to enhance tumor cell killing. GZ17-6.02 interacted in a greater than additive fashion with olaparib to kill prostate cancer cells, regardless of androgen receptor expression or loss of PTEN function. Mechanistically, GZ17-6.02 initially caused peri-nuclear activation of ataxia-telangiectasia mutated (ATM) that was followed after several hours by activation of nuclear ATM, and which at this time point was associated with increased levels of DNA damage. Directly downstream of ATM, GZ17-6.02 and olaparib cooperated to activate the AMP-dependent protein kinase (AMPK) which then activated the kinase ULK1, resulting in autophagosome formation that was followed by autophagic flux. Knock down of ATM, AMPK\u03b1 or the autophagy-regulatory proteins Beclin1 or ATG5 significantly reduced tumor cell killing. GZ17-6.02 and olaparib cooperated to activate protein kinase R which phosphorylated and inactivated eIF2\u03b1, i.e., enhanced endoplasmic reticulum (ER) stress signaling. Knock down of eIF2\u03b1 also significantly reduced autophagosome formation and tumor cell killing. We conclude that GZ17-6.02 and olaparib interact to kill prostate cancer cells <jats:italic>in vitro<\/jats:italic> by increasing autophagy and by enhancing ER stress signaling. <jats:italic>In vivo<\/jats:italic>, GZ17-6.02 as a single agent profoundly reduced tumor growth and significantly prolonged animal survival. GZ17-6.02 interacted with olaparib to further suppress the growth of LNCaP tumors without ultimately enhancing animal survival. Our data support the consideration of GZ17-6.02 as a possible therapeutic agent in patients with AR+ prostate cancer.<\/jats:p>","DOI":"10.3389\/fonc.2022.1045459","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:40:22Z","timestamp":1667497222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["GZ17-6.02 kills prostate cancer cells in vitro and in vivo"],"prefix":"10.3389","volume":"12","author":[{"given":"Laurence","family":"Booth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Dent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29464","article-title":"GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy","volume":"235","author":"Booth","year":"2020","journal-title":"J Cell Physiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.711043","article-title":"GZ17-6.02 and pemetrexed interact to kill osimertinib-resistant NSCLC cells that express mutant ERBB1 proteins","volume":"11","author":"Booth","year":"2021","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.656453","article-title":"GZ17-6.02 interacts with [MEK1\/2 and b-RAF inhibitors] to kill melanoma cells","volume":"11","author":"Booth","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.18632\/oncotarget.28177","article-title":"GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells","volume":"13","author":"Booth","year":"2022","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1764905","article-title":"A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses","volume":"33","author":"West","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29580","article-title":"[Curcumin + sildenafil] enhances the efficacy of 5FU and anti-PD1 therapies in vivo","volume":"235","author":"Dent","year":"2020","journal-title":"J Cell Physiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2022.01.004","article-title":"J Cancer healthcare disparities among African americans in the united states","volume":"114","author":"Mitchell","year":"2022","journal-title":"Natl Med Assoc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"215619","DOI":"10.1016\/j.canlet.2022.215619","article-title":"Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy","volume":"534","author":"Fontana","year":"2022","journal-title":"Cancer Lett"},{"key":"B9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/14737140.2022.2020651","article-title":"Current androgen receptor antagonists under investigation for resistant prostate cancer","volume":"22","author":"Nigro","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2022.01.037","article-title":"Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors","volume":"166","author":"Paulet","year":"2022","journal-title":"Eur J Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10565-007-9043-9","article-title":"Comet assay measurements: A perspective","volume":"25","author":"Kumaravel","year":"2009","journal-title":"Cell Biol Toxicol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0921-8777(94)00043-6","article-title":"The kinetics of repair of oxidative DNA damage (strand breaks and oxidised pyrimidine) in human cells","volume":"336","author":"Collins","year":"1995","journal-title":"Mutat Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1385\/MB:26:3:249","article-title":"Comet assay for DNA damage and repair: principles, applications and limitations","volume":"26","author":"Collins","year":"2004","journal-title":"Mol Biotechnol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2014.12.007","article-title":"Roles of the translation initiation factor eIF2alpha serine 51 phosphorylation in cancer formation and treatment","volume":"1849","author":"Koromilas","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2013.07.030","article-title":"Small molecule modulators of eukaryotic initiation factor 2 alpha kinases, the key regulators of protein synthesis","volume":"95","author":"Joshi","year":"2013","journal-title":"Biochimie"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/ijms18102213","article-title":"Kinases of eIF2a switch translation of mRNA subset during neuronal plasticity","volume":"18","author":"Ekaterina Chesnokova","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19582-3","article-title":"Co-Regulation of the transcription controlling ATF2 phospho-switch by JNK and p38","volume":"11","author":"Kirsch","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203448","article-title":"Activation of NF-\u03baB by the dsRNA-dependent protein kinase, PKR involves the I\u03baB kinase complex","volume":"19","author":"Gil","year":"2000","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.7.4653","article-title":"Induction of apoptosis by double-Stranded-RNA-Dependent protein kinase (PKR) involves the \u03b1 subunit of eukaryotic translation initiation factor 2 and NF-\u03baB","volume":"19","author":"Gil","year":"1999","journal-title":"Mol Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.9.3052-3066.2003","article-title":"Bile acid regulation of C\/EBPbeta, CREB, and c-jun function, via the extracellular signal-regulated kinase and c-jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes","volume":"23","author":"Qiao","year":"2003","journal-title":"Mol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.chembiol.2020.08.014","article-title":"Discovery of covalent MKK4\/7 dual inhibitor","volume":"27","author":"Jiang","year":"2020","journal-title":"Cell Chem Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.1c00376","article-title":"Rational design, optimization, and biological evaluation of novel MEK4 inhibitors against pancreatic adenocarcinoma","volume":"12","author":"Kwong","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.12917","article-title":"Paclitaxel induces apoptosis through the TAK1-JNK activation pathway","volume":"10","author":"Yu-Wei","year":"2020","journal-title":"FEBS Open Bio."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107538","DOI":"10.1016\/j.pharmthera.2020.107538","article-title":"NF-\u03baB signaling promotes castration-resistant prostate cancer initiation and progression","volume":"211","author":"Thomas-Jardin","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgl034","article-title":"Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression","volume":"27","author":"Uzzo","year":"2006","journal-title":"Carcinogenesis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29852","article-title":"A phosphomimetic mutant of RelA\/p65 at Ser536 induces apoptosis and senescence: An implication for tumor-suppressive role of Ser536 phosphorylation","volume":"138","author":"Bu","year":"2016","journal-title":"Int J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26704","article-title":"Super-enhancers: novel target for pancreatic ductal adenocarcinoma","volume":"10","author":"Ghosh","year":"2019","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7150\/thno.30834","article-title":"High OGT activity is essential for MYC-driven proliferation of prostate cancer cells","volume":"9","author":"Itkonen","year":"2019","journal-title":"Theranostics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.3390\/ijms20122883","article-title":"Dysregulated transcriptional control in prostate cancer","volume":"20","author":"Baumgart","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-020-00137-0","article-title":"Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets","volume":"4","author":"Chen","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9922-7","article-title":"Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery","volume":"31","author":"Bundred","year":"2013","journal-title":"Invest New Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1045459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:40:27Z","timestamp":1667497227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1045459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":32,"alternative-id":["10.3389\/fonc.2022.1045459"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1045459","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"article-number":"1045459"}}